Shenzhen Kangzhe, a Subsidiary of China Medical System (867.HK), Honored as One of the “2021 Shenzhen Top 500 Enterprises”

Company News

On October 29, 2021, Shenzhen Enterprise Federation and Shenzhen Enterprise Directors Association released the list of “2021 Shenzhen Top 500 Enterprises”, and Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS”) was once again selected, ranking 131.

Shenzhen Kangzhe has always adhered to the concepts of prudence, innovation and compliance. Leveraging the international R&D resources of CMS, Shenzhen Kangzhe has continuously introduced differentiated and quality medicines that can meet the unmet clinical needs to the Chinese pharmaceutical market, creating value for Chinese doctors and patients.

As an outstanding group of Shenzhen enterprises, Shenzhen Top 500 Enterprises are vital forces in the economic development of Shenzhen. Shenzhen Kangzhe will seize the opportunity brought by the construction of the Guangdong-Hong Kong-Macao Greater Bay Area as well as the Pioneering Demonstration Zone of Socialism with Chinese Characteristics, and play a stronger role in implementing the new development concepts and promoting the innovation-driven high-quality development.